FDA Ad Division Letter Surge Shows Focus On Prominence Of Risk Information
Executive Summary
An upcoming FDA draft guidance on fair balance in promotional materials could benefit manufacturers following a spate of warning letters from the agency's ad division citing the prominence of risk information
You may also be interested in...
FDA's Advertising Letters Continue To Grow, Both In Volume And Depth
FDA's Division of Drug Marketing, Advertising and Communication appears to be shifting the way it writes citations to firms, increasing not just the number of letters it sends, but the number of problems it lists within each letter
FDA's Advertising Letters Continue To Grow, Both In Volume And Depth
FDA's Division of Drug Marketing, Advertising and Communication appears to be shifting the way it writes citations to firms, increasing not just the number of letters it sends, but the number of problems it lists within each letter
Watching Your Language: FDA Ad Division Objects To User-Friendly Efficacy Claims With Jargon-y Risk Info
FDA expects drug advertisements to use the same level of language to convey both safety and efficacy information, according to a pair of letters from the Division of Drug Marketing, Advertising and Communications